These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
538 related articles for article (PubMed ID: 25511792)
41. End of dose interval symptoms in patients treated with natalizumab: A role for serum cytokines? Cathérine D; Annelien P; Anne S; Luc A; Liesbeth VH; Gerlo S; Guy L Mult Scler Relat Disord; 2020 Jun; 41():102020. PubMed ID: 32146430 [TBL] [Abstract][Full Text] [Related]
42. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. Kaufman M; Pardo G; Rossman H; Sweetser MT; Forrestal F; Duda P J Neurol Sci; 2014 Jun; 341(1-2):22-7. PubMed ID: 24731783 [TBL] [Abstract][Full Text] [Related]
43. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027 [TBL] [Abstract][Full Text] [Related]
44. Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study. Sundgren M; Piehl F; Wahlin Å; Brismar T Mult Scler Relat Disord; 2016 Nov; 10():36-43. PubMed ID: 27919496 [TBL] [Abstract][Full Text] [Related]
45. Walking capacity and ability are more impaired in progressive compared to relapsing type of multiple sclerosis. Feys P; Bibby BM; Baert I; Dalgas U Eur J Phys Rehabil Med; 2015 Apr; 51(2):207-10. PubMed ID: 25180640 [TBL] [Abstract][Full Text] [Related]
47. Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study. Planche V; Moisset X; Morello R; Dumont E; Gibelin M; Charré-Morin J; Saubusse A; Mondou A; Reuter F; Defer G; Pelletier J; Brochet B; Clavelou P J Neurol Sci; 2017 Nov; 382():148-154. PubMed ID: 29111011 [TBL] [Abstract][Full Text] [Related]
48. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis. Rinaldi F; Calabrese M; Seppi D; Puthenparampil M; Perini P; Gallo P Mult Scler; 2012 Dec; 18(12):1760-7. PubMed ID: 22570359 [TBL] [Abstract][Full Text] [Related]
49. Walking speed, rather than Expanded Disability Status Scale, relates to long-term patient-reported impact in progressive MS. Bosma L; Kragt JJ; Polman CH; Uitdehaag BM Mult Scler; 2013 Mar; 19(3):326-33. PubMed ID: 22907939 [TBL] [Abstract][Full Text] [Related]
50. Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation. Mustonen T; Rauma I; Hartikainen P; Krüger J; Niiranen M; Selander T; Simula S; Remes AM; Kuusisto H Mult Scler Relat Disord; 2020 Feb; 38():101498. PubMed ID: 31864192 [TBL] [Abstract][Full Text] [Related]
51. Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report. Patti F; Leone C; Zappia M BMC Neurol; 2015 Dec; 15():252. PubMed ID: 26643473 [TBL] [Abstract][Full Text] [Related]
52. Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial. Nakamura K; Sun Z; Hara-Cleaver C; Bodhinathan K; Avila RL Mult Scler; 2024 May; 30(6):687-695. PubMed ID: 38469809 [TBL] [Abstract][Full Text] [Related]
53. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Balcer LJ; Galetta SL; Calabresi PA; Confavreux C; Giovannoni G; Havrdova E; Hutchinson M; Kappos L; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA Neurology; 2007 Apr; 68(16):1299-304. PubMed ID: 17438220 [TBL] [Abstract][Full Text] [Related]
54. A 3meter Timed Tandem Walk is an early marker of motor and cerebellar impairment in fully ambulatory MS patients. Stellmann JP; Vettorazzi E; Poettgen J; Heesen C J Neurol Sci; 2014 Nov; 346(1-2):99-106. PubMed ID: 25156343 [TBL] [Abstract][Full Text] [Related]
55. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study. Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960 [TBL] [Abstract][Full Text] [Related]
56. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary]. Mezei Z; Bereczki D; Csiba L; Csépány T Ideggyogy Sz; 2006 Nov; 59(11-12):442-7. PubMed ID: 17203882 [TBL] [Abstract][Full Text] [Related]
57. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H; Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031 [TBL] [Abstract][Full Text] [Related]
58. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Calabresi PA; Giovannoni G; Confavreux C; Galetta SL; Havrdova E; Hutchinson M; Kappos L; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Lublin FD; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; Neurology; 2007 Oct; 69(14):1391-403. PubMed ID: 17761550 [TBL] [Abstract][Full Text] [Related]
60. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice. Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R; Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]